SSY Group Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

SSY Group verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 9.4%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 5.7%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 10.5%. Die Eigenkapitalrendite von SSY Group beträgt 18.2% und die Nettomargen betragen 21.1%.

Wichtige Informationen

9.4%

Wachstumsrate der Gewinne

9.9%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	5.6%
Wachstumsrate der Einnahmen	10.5%
Eigenkapitalrendite	18.2%
Netto-Marge	21.1%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 31

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Mar 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Mar 28

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

Mar 06

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Feb 13

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

Dec 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Sep 26

SSY Group (HKG:2005) Will Pay A Larger Dividend Than Last Year At HK$0.07

Sep 03

If EPS Growth Is Important To You, SSY Group (HKG:2005) Presents An Opportunity

Aug 31

Estimating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Jun 24

Aufschlüsselung der Einnahmen und Ausgaben

Wie SSY Group Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

SEHK:2005 Einnahmen, Ausgaben und Erträge (HKD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	6,469	1,366	1,679	288
31 Mar 24	6,466	1,342	1,760	289
31 Dec 23	6,463	1,319	1,840	290
30 Sep 23	6,413	1,255	1,881	282
30 Jun 23	6,363	1,191	1,921	273
31 Mar 23	6,398	1,157	1,936	266
31 Dec 22	6,434	1,123	1,950	259
30 Sep 22	6,376	1,101	2,020	267
30 Jun 22	6,318	1,080	2,090	274
31 Mar 22	5,838	933	2,040	261
31 Dec 21	5,357	786	1,990	248
30 Sep 21	5,139	713	2,025	212
30 Jun 21	4,921	641	2,060	175
31 Mar 21	4,591	626	1,977	151
31 Dec 20	4,261	612	1,894	127
30 Sep 20	4,177	723	1,766	88
30 Jun 20	4,093	835	1,638	50
31 Mar 20	4,364	985	1,641	25
31 Dec 19	4,636	1,136	1,643	0
30 Sep 19	4,525	1,075	1,628	0
30 Jun 19	4,414	1,014	1,613	0
31 Mar 19	4,297	963	1,590	0
31 Dec 18	4,181	912	1,566	0
30 Sep 18	4,012	867	1,477	0
30 Jun 18	3,844	822	1,387	0
31 Mar 18	3,460	743	1,175	0
31 Dec 17	3,076	665	962	0
30 Sep 17	2,827	616	826	0
30 Jun 17	2,577	567	689	0
31 Mar 17	2,469	528	652	0
31 Dec 16	2,361	490	615	0
30 Sep 16	2,315	426	620	0
30 Jun 16	2,270	363	624	0
31 Mar 16	2,246	383	591	0
31 Dec 15	2,222	403	559	0
30 Sep 15	2,189	443	533	0
30 Jun 15	2,156	482	507	0
31 Mar 15	2,124	487	496	0
31 Dec 14	2,091	492	484	0
30 Jun 14	1,309	402	233	0
31 Mar 14	1,516	386	330	0
31 Dec 13	1,723	369	427	0

Qualität der Erträge: 2005 hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: 2005Die aktuellen Gewinnspannen (21.1%) sind höher als im letzten Jahr (18.7%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: 2005In den letzten 5 Jahren sind die Gewinne von 9.4% jährlich gestiegen.

Beschleunigtes Wachstum: 2005Das Gewinnwachstum des Unternehmens im letzten Jahr (14.6%) übertrifft seinen 5-Jahres-Durchschnitt (9.4% pro Jahr).

Erträge im Vergleich zur Industrie: 2005 Das Gewinnwachstum im vergangenen Jahr (14.6%) übertraf das der Branche Pharmaceuticals 6.4% .

Eigenkapitalrendite

Hohe Eigenkapitalrendite: 2005Die Eigenkapitalrendite des Unternehmens (18.2%) wird als niedrig angesehen.

SSY Group Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023)

SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

First half 2023 earnings released: EPS: HK$0.21 (vs HK$0.19 in 1H 2022)

SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023

Recent updates

Chairman & CEO recently bought HK$3.4m worth of stock

Price target increased by 14% to HK$6.38

SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)

SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China

SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China

Investor sentiment improves as stock rises 18%

Chairman & CEO recently bought HK$4.8m worth of stock

Analysts Just Slashed Their SSY Group Limited (HKG:2005) EPS Numbers

SSY Group Limited Announces Update on Product Development

Chairman & CEO recently bought HK$1.5m worth of stock

Consensus EPS estimates fall by 10%

Price target decreased by 10% to HK$5.58

SSY Group Limited Announces Update on Product Development

First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023)

SSY Group's (HKG:2005) Dividend Will Be HK$0.08

First half dividend increased to HK$0.08

SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024

SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited's (HKG:2005) P/E Is On The Mark

Investor sentiment deteriorates as stock falls 16%

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China

Upcoming dividend of HK$0.10 per share

SSY Group (HKG:2005) Is Paying Out A Larger Dividend Than Last Year

SSY Group's (HKG:2005) Upcoming Dividend Will Be Larger Than Last Year's

SSY Group Limited Provides Update on Product Development

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Chairman & CEO recently bought HK$2.5m worth of stock

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

SSY Group Limited, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China

SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market

SSY Group Limited Receives Approval for Gliclazide Tablet

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Ssy Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

SSY Group Limited Provides Update on Product Development

Chairman & CEO recently bought HK$4.7m worth of stock

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045

SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023

SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection